Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

To evaluate the role of V3-specific IgG antibodies (Abs) in the RV144 clinical HIV vaccine trial, which reduced HIV-1 infection by 31.2%, the anti-V3 Ab response was assessed. Vaccinees' V3 Abs were highly cross-reactive with cyclic V3 peptides (cV3s) from diverse virus subtypes. Sieve analysis...

Full description

Bibliographic Details
Main Authors: Zolla-Pazner, Susan, Edlefsen, Paul T., Rolland, Morgane, Kong, Xiang-Peng, deCamp, Allan, Gottardo, Raphael, Williams, Constance, Tovanabutra, Sodsai, Sharpe-Cohen, Sandra, Mullins, James I., deSouza, Mark S., Karasavvas, Nicos, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Pitisuttihum, Punnee, Kaewkungwal, Jaranit, O'Connell, Robert J., Robb, Merlin L., Michael, Nelson L., Kim, Jerome H., Gilbert, Peter
Format: Online
Language:English
Published: Elsevier 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293639/